Tvardi Therapeutics (TVRD) Enterprise Value: 2013-2017
Historic Enterprise Value for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2017 value amounting to $399.1 million.
- Tvardi Therapeutics' Enterprise Value rose 104.49% to $399.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $399.1 million, marking a year-over-year increase of 797.21%. This contributed to the annual value of $28.0 million for FY2024, which is 30.89% down from last year.
- According to the latest figures from Q4 2017, Tvardi Therapeutics' Enterprise Value is $399.1 million, which was up 16.34% from $343.1 million recorded in Q3 2017.
- In the past 5 years, Tvardi Therapeutics' Enterprise Value ranged from a high of $465.3 million in Q1 2017 and a low of -$21.2 million during Q2 2013.
- In the last 3 years, Tvardi Therapeutics' Enterprise Value had a median value of $255.6 million in 2015 and averaged $259.4 million.
- Per our database at Business Quant, Tvardi Therapeutics' Enterprise Value spiked by 51,318.41% in 2014 and then slumped by 80.15% in 2016.
- Quarterly analysis of 5 years shows Tvardi Therapeutics' Enterprise Value stood at -$12.4 million in 2013, then soared by 1,511.66% to $174.4 million in 2014, then surged by 102.01% to $352.4 million in 2015, then slumped by 44.61% to $195.2 million in 2016, then spiked by 104.49% to $399.1 million in 2017.
- Its Enterprise Value was $399.1 million in Q4 2017, compared to $343.1 million in Q3 2017 and $387.9 million in Q2 2017.